All In Biotech

Drug Trial Radar · NCT05255822

INNA-051 Influenza Challenge Study

Phase 2a Study in Healthy Adult Participants Pre-treated With INNA-051 and Challenged With Influenza Virus

Last checked: Nov 20, 2026Latest source record: Jan 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 123 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

123

Actual

Start

Feb 28, 2022

Primary completion

Aug 23, 2022

Study completion Aug 23, 2022

Sponsor

Lead sponsor
ENA Respiratory Pty LtdIndustry
Sponsor type
Industry
First posted
Feb 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in healthy adults, administered prior to administration of an influenza challenge virus. This study will evaluate 2 active dose levels of INNA-051 and placebo.

Conditions

  • Influenza Prophylaxis

Interventions

  • INNA-051Drug

    Liquid for intra-nasal administration

  • PlaceboOther

    Liquid for intra-nasal administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the antiviral effect of INNA-051 compared to placebo against influenza virusTime frame: To Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • hVIVO

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.